TickerFacts.

Company research / ABT

Abbott Laboratories (ABT)

Build a valuation ↗↓ Download CSV

SEC name ABBOTT LABORATORIES · CIK 0000001800 · NYSE · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated IL
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Abbott Laboratories reported revenue of $44.33B. Revenue grew 5.7% from the prior annual period. Over the twelve months to 2026-03-31, revenue was $45.13B.

Key ratios (year ended 2025-12-31)

56.4%
Gross margin (computed)
18.2%
Operating margin
14.7%
Net margin
12.5%
Return on year-end equity
5.7%
Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-02

Headquarters locality: North Chicago · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-03-31 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-03-31		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$45.13B$44.33B$41.95B$40.11B$43.65B$43.08B$34.61B$31.90B$30.58B$27.39B$20.85B
Cost of Revenue$19.74B$19.32B$18.71B$17.98B$19.14B$18.54B$15.00B$13.23B$12.71B$12.41B$9.09B
Gross Profit (computed)$25.39B$25.01B$23.24B$22.13B$24.51B$24.54B$19.61B$18.67B$17.87B$14.98B$11.76B
R&D Expense$2.99B$2.94B$2.84B$2.74B$2.89B$2.74B$2.42B$2.44B$2.30B$2.26B$1.45B
Operating Income$7.71B$8.05B$6.83B$6.48B$8.36B$8.43B$5.36B$4.53B$3.65B$1.56B$3.03B
Net Income$6.28B$6.52B$13.40B$5.72B$6.93B$7.07B$4.50B$3.69B$2.37B$477.00M$1.40B
EPS (Diluted)n/a$3.72$7.64$3.26$3.91$3.94$2.50$2.06$1.33$0.27$0.94
Total Assets$110.43B$86.71B$81.41B$73.21B$74.44B$75.20B$72.55B$67.89B$67.17B$76.25B$52.67B
Long-Term Debtn/a$12.93B$14.12B$14.68B$16.77B$18.05B$18.53B$17.94B$19.37B$27.72B$20.68B
Shareholders' Equity$52.06B$52.13B$47.66B$38.60B$36.69B$35.80B$32.78B$31.09B$30.52B$30.90B$20.54B
Cash & Equivalents$6.80B$8.52B$7.62B$6.90B$9.88B$9.80B$6.84B$3.86B$3.84B$9.41B$18.62B
Operating Cash Flow$9.46B$9.57B$8.56B$7.26B$9.58B$10.53B$7.90B$6.14B$6.30B$5.57B$3.20B
Capital Expenditures$2.09B$2.17B$2.21B$2.20B$1.78B$1.89B$2.18B$1.64B$1.39B$1.14B$1.12B
Free Cash Flow$7.38B$7.39B$6.35B$5.06B$7.80B$8.65B$5.72B$4.50B$4.91B$4.43B$2.08B
Share Repurchases$793.00M$893.00M$1.29B$1.23B$3.79B$2.30B$403.00M$718.00M$238.00M$117.00M$522.00M
Dividends Paid$4.19B$4.12B$3.84B$3.56B$3.31B$3.20B$2.56B$2.27B$1.97B$1.85B$1.54B
Dividends Per Sharen/a$2.40$2.24$2.08$1.92n/an/an/an/an/an/a
Weighted Average Diluted Sharesn/a1.75B1.75B1.75B1.76B1.79B1.79B1.78B1.77B1.75B1.48B
EPS (Basic)n/a$3.73$7.67$3.28$3.94$3.97$2.52$2.07$1.34$0.27$0.94

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView